A Comparative Study of Serum C-reactive Protein Level Between Pre-eclampsia and Normal Pregnancy in Tertiary Level Hospital
Authors: Jannat S, Islam A, Yesmin S, Shanta FI, Jabin AM, Sanjida S, Trishna D
Journal: Clinical Pathology & Research Journal. Article type: Research Article. Published: 2025-12-16. DOI: https://doi.org/10.23880/cprj-16000217
Abstract
Perivascular epithelioid cell tumors (PEComas) represent a rare family of mesenchymal neoplasms with distinctive morphological and immunophenotypic features. Gastrointestinal PEComas constitute an uncommon subset with variable clinical behavior, ranging from benign localized lesions to malignant and metastatic neoplasms. Accurate diagnosis requires integration of histologic features, immunohistochemical analysis demonstrating myomelanocytic differentiation, and exclusion of mimics such as gastrointestinal stromal tumors, metastatic melanoma, and epithelioid smooth muscle tumors. Central to the pathogenesis of PEComas is dysregulation of the mTOR signaling pathway. TSC1 and TSC2 alterations underlie mTOR activation in a significant proportion of conventional PEComas, whereas a subset of cases harbor TFE3 gene rearrangements that define a biologically and clinically distinct subgroup. These molecular features not only clarify pathogenetic mechanisms but also support targeted therapeutic strategies, most notably mTOR inhibitors, which have demonstrated meaningful clinical activity in advanced or unresectable disease. Risk stratification remains challenging, as existing criteria—particularly those proposed by Folpe and colleagues—were developed from heterogeneous cohorts and incompletely predict behavior in gastrointestinal sites. Emerging evidence suggests the incorporation of additional features such as Ki-67 index, necrosis, mitotic activity, and molecular alterations may improve prognostic accuracy. Comprehensive surgical excision remains the primary treatment for localized tumors, while systemic therapy, particularly mTOR pathway inhibition, is reserved for recurrent, unresectable, or metastatic disease. Continued multidisciplinary collaboration, expanded molecular profiling, and development of prospective registries are essential to refine risk prediction, therapeutic selection, and long-term management of gastrointestinal PEComas.
Keywords: PEComa, Gastrointestinal tract, mTOR pathway, TFE3 rearrangement, Molecular diagnostics, Targeted therapy
Jannat S¹, Islam A¹, Yesmin S²*, Shanta FI³, Jabin AM³, Sanjida S⁴ and Trishna D⁵
**Keywords:** Serum C-reactive Protein; Pre-eclampsia; Normal Pregnancy; Pathophysiology
Abbreviations
CRP: C-Reactive Protein; IMCH: International Medical College and Hospital; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; SPSS: Statistical Package for Social Science.
Introduction
Pre-eclampsia is most common medical complication during pregnancy. It is a multisystem disorder of pregnancy which is characterized by new onset of hypertension. It is recorded as one of the top five causes of maternal death in the world. Here hypertension (SBP and DBP is ≥140 and 90 mm of Hg respectively) on two occasions, at least two hours apart and proteinuria (protein excretion of ≥ 300 mg in a 2 hours’ urine collection, or a dipstick of ≥ 2+), that develop after 20 weeks of gestation in previously normotensive woman [1]. The pathophysiology of pre-eclampsia remain is uncertain despite of a failure of the trophoblastic invasion of the uterine blood vessels. Immunological intolerance leading to maladaptation of maternal spiral arterioles which may be associated with a vascular resistance of the uterine artery and decrease perfusion of the placenta [2,3].
Pre-eclampsia is characterized by the development of hypertension, proteinuria and oedema at 20th week of gestation. Placenta into maternal plasma plays a central role in the ensuring endothelial dysfunction that is the prominent feature of this disease. Here the exact aetiology of eclampsia is still unknown.
This is a transient and serious complication of pregnancy that approximately affect 2-4% of all pregnancies. It is a major cause of maternal & perinatal morbidity & mortality worldwide particularly in developing countries. All over the world pre- eclampsia is in the third position for maternal mortality and in 7th position of the perinatal mortality. On average 50,000 to 60,000 woman dies in each year and it is now a global leading cause out of which 9% of maternal death is in Asia [4,5]. In spite of various attempts to understand the primary aetiology behind this vascular endothelial dysfunction and inflammation are considered to have a crucial role in pre-eclampsia. Pre- eclampsia developed in 4-5% of human pregnancies. Pre- eclampsia is characterized by elevated blood pressure and proteinuria which developed after 20 weeks of gestational age [3,5]. Pre-eclampsia can result in eclampsia when convulsions develop or other manifestations as haemolysis and increased liver enzymes & low platelet count which all together known as HELLP syndrome. Endothelial dysfunction and inflammation are considered to have a crucial role in a pathophysiological mechanism of pre-eclampsia [3]. CRP is an acute phase protein which is synthesized in hepatocytes. CRP is an important marker of systemic inflammation and it has been shown that CRP is elevated in woman with pre-eclampsia [4,5].
It is therefore important to identify woman who are in high risk of developing the disease early in pregnancy. This is because very early identification of CRP level as a biochemical marker of the disease would not only facilitate selective recruiting of those at increased risk for pre-eclampsia but also help in determining those patients who were more likely to get benefit from interventional measures. This study will also help to get idea about the level of serum CRP in pre-eclampsia and its relationship with the severity of the disease.
Material and Methods
A cross-sectional study was conducted in the clinical pathology department of IMCH, Gazipur from January 2018 to December 2018. Total number of 150 pregnant women in third trimester of pregnancy attending in Obstetrics’ and gynaecology department of IMCH and Digital Diagnostic and Hospital were selected as study subjects.
Among them 75 patients were diagnosed as case of pre- eclampsia were selected as group I with age range 18-36 years and 75 age matched normal healthy woman as group II. Pregnant woman with pre-existing hypertension, diabetes mellitus and renal disease were excluded from the study by history, clinical examination and relevant laboratory investigations. After obtaining informed written consent from all the study subjects relevant data were documented in a predefined data sheet. With maintaining all aseptic precautions, blood samples were collected from all the study subjects for estimation of serum CRP level. Serum CRP level was measured by ELISA method.
Statistical analysis was performed by using computer- based software, Statistical package for social science (SPSS) for windows version 20. Mean values of differences between two groups by using students unpaired “t” test. Chi-square test was performed to find out the statistical difference regarding qualitative variables between two group. For all statistical analysis “p” value
Results
The study included parameters in terms such as anti- natal checkup, Blood pressure (BP), BMI are shown in Table 1-3. There are 75 pregnant women with pre-eclampsia (severe pre-eclampsia) and 75 normal pregnant women. In this study, it was observed that anti-natal check-up of group I was significant compared to group II and on the other hand regular antenatal checkup more in group II (75.0%) than group I (52.0%). The difference was statistically significant (P
Discussion
Pre-eclampsia is not merely hypertension unmasked by pregnancy. It is a significant cause of maternal and perinatal mortality and morbidity. Hypertension seems to be a marker of the disorder rather than a causal factor. Thus success in treating pre-eclampsia is not merely reducing BP rather ameliorating the syndrome itself including improved perinatal outcome, the major complication of the management strategy of early delivery.
This cross sectional study was carried out with an aim to compare CRP level in pre-eclampsia woman and normal pregnant woman. Frequency of regular antenatal check up was more in normal pregnant group compared to pre- eclampsia group. The difference was statistically significant (p 90 mm of Hg) in group I (100%) compared to group II (8%) (Table 3). Another previous study showed the mean SBP and DBP were high in pre-eclampsia group compared to normal pregnant group. The difference was statistically significant (p
Conclusion
The findings of this study showed that higher CRP level was associated with pre-eclampsia. This supports the hypothesis that alteration of this serum marker CRP may take a role in the etiology of pre-eclampsia. So far early diagnosis and prevention of pre-eclampsia, regular antenatal checkup and routine investigation of CRP should be advocated. As well as further trials are needed regarding the role of early detection of CRP in reduction of systemic complications and maternal death due to pre-eclampsia.
References
1. Sibai B, Baha M, Dekker G (2003) Diagnosis and management of gestational hypertension and pre- eclampsia, Obstetrics and Gynaecology. Journal of Dental and Medical sciences 102(1): 181-192.
2. Luis B, Alice S, Murlel C, Irene R (2003) Neutrophil activation and c reactive protein concentration in pre-eclampsia. American journal of Obstetrics and Gynaecology 22(2): 129-141.
3. Anil B, Jayashree A, Ganu J, Nitin N (2011) Serum Hs-CRP and uric acid as indication of severity in Pre-eclampsia. International Journal of Pharmacology and Bio-sciences 2(3): 340-345.
4. Kameswaramma K, Lim K, Jeffery L, Cher E (2014) Estimation of C-reactive Protein, Magnesium and uric acid levels in pre-eclampsia patients in comparison with noemal pregnant woman. Scientific Journal of Applied Medical Sciences 2(23): 628-632.
5. Power R, Bodnar L, Ness R, Cooper K (2006) CRP concentrations in early pregnancy among pre-eclampsic women and normal pregnant women. American journal of Obstetrics and Gynaecology 28(6): 160-172.
6. Mandal K, Premchandra Y, Arpita D, Gyaneshwar W (2015) Serum uric acid and CRP in pre-eclampsia. International Journal of Clinical Biochemistry 14(2): 116-123.
7. Ayatollah H, Hasanzade N, Farzadnia Mahdi, Rahmanian A (2007) Serum level of HS-Creactive Protein in normal and Pre-eclampsic Pregnancies. Iranian Journal of Pathology 2(3): 100-104.
8. Guvan M, Coskun A, Ertas E, Aral M (2009) Association of maternal serum CRP, IL-6, TNF α, Vit B12 levels with the severity of Pre-eclampsia and fetal birth weight, Hypertersion in pregnancy. International Journal of Clinical Biochemistry 28(3): 190-200.
9. Qin C, Luthy D, Zhang C, Walash S (2004) A progressive study of maternal serum C-reactive Protein concentration and risk of Pre-eclampsia. American journal of Obstetrics and Gynaecology 17(2): 154- 160.
10. Yu H, Rafai N, Leveno K, Gant N (2000) High sensitivity C-reactive Protein in pre-eclampsia and Normal Pregnant women. British journal of Obstetrics and Gynaecology 33(8): 601-610.
11. Kupfermine M, Aderka D, Sokal M, Wallach D (2009) Soluble tumour necrosis factor receptors and Interleukin-6 and CRP levels in patients with Severe Pre-eclampsia. International Journal of Obstetrics and Gynaecology 88(3): 420-427.
12. Belo L, Caslake M, Sritos S, Cooney J (2003) Neutrophil activation and C-reactive protein Concentration in Pre- eclampsia. European Journal of Obstetrics. Gynaecology and Reproductive Biology 22(2): 121-125.
Distribution of serum CRP in study subjects.
Distribution of the study subjects by BMI.
Distribution of the study subjects by BMI.
Distribution of the study subjects by BP.
References
- Sibai B, Baha M, Dekker G (2003) Diagnosis and management of gestational hypertension and pre- eclampsia, Obstetrics and Gynaecology. Journal of Dental and Medical sciences 102(1): 181-192.
- Luis B, Alice S, Murlel C, Irene R (2003) Neutrophil activation and c reactive protein concentration in pre-eclampsia. American journal of Obstetrics and Gynaecology 22(2): 129-141.
- Anil B, Jayashree A, Ganu J, Nitin N (2011) Serum Hs-CRP and uric acid as indication of severity in Pre-eclampsia. International Journal of Pharmacology and Bio-sciences 2(3): 340-345.
- Kameswaramma K, Lim K, Jeffery L, Cher E (2014) Estimation of C-reactive Protein, Magnesium and uric acid levels in pre-eclampsia patients in comparison with noemal pregnant woman. Scientific Journal of Applied Medical Sciences 2(23): 628-632.
- Power R, Bodnar L, Ness R, Cooper K (2006) CRP concentrations in early pregnancy among pre-eclampsic women and normal pregnant women. American journal of Obstetrics and Gynaecology 28(6): 160-172.
- Mandal K, Premchandra Y, Arpita D, Gyaneshwar W (2015) Serum uric acid and CRP in pre-eclampsia. International Journal of Clinical Biochemistry 14(2): 116-123.
- Ayatollah H, Hasanzade N, Farzadnia Mahdi, Rahmanian A (2007) Serum level of HS-Creactive Protein in normal and Pre-eclampsic Pregnancies. Iranian Journal of Pathology 2(3): 100-104.
- Guvan M, Coskun A, Ertas E, Aral M (2009) Association of maternal serum CRP, IL-6, TNF α, Vit B12 levels with the severity of Pre-eclampsia and fetal birth weight, Hypertersion in pregnancy. International Journal of Clinical Biochemistry 28(3): 190-200.
- Qin C, Luthy D, Zhang C, Walash S (2004) A progressive study of maternal serum C-reactive Protein concentration and risk of Pre-eclampsia. American journal of Obstetrics and Gynaecology 17(2): 154- 160.
- Yu H, Rafai N, Leveno K, Gant N (2000) High sensitivity C-reactive Protein in pre-eclampsia and Normal Pregnant women. British journal of Obstetrics and Gynaecology 33(8): 601-610.
- Kupfermine M, Aderka D, Sokal M, Wallach D (2009) Soluble tumour necrosis factor receptors and Interleukin-6 and CRP levels in patients with Severe Pre-eclampsia. International Journal of Obstetrics and Gynaecology 88(3): 420-427.
- Belo L, Caslake M, Sritos S, Cooney J (2003) Neutrophil activation and C-reactive protein Concentration in Pre- eclampsia. European Journal of Obstetrics. Gynaecology and Reproductive Biology 22(2): 121-125.